TGNA:FRA
Transgene SA
0,66 €
arrow_upward
+0,30%(+0,0020) 1d
19 d’oct., 8:06:17 GMT+2 · EUR
search
Tots els sĂmbols
| SĂmbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadĂstiques principals per a TGNA...
Obre
0,66 €
Alt
0,66 €
Baix
0,66 €
CapitalitzaciĂł borsĂ ria
189,70Â M
Volum mitjĂ
0,00
Volum
0,00
Alt 52 setmanes
1,48 €
Baix 52 setmanes
0,60 €
BPA
-0,17 €
Nombre d'empleats
152
Obre
0,66 €
Alt
0,66 €
Baix
0,66 €
CapitalitzaciĂł borsĂ ria
189,70Â M
Volum mitjĂ
0,00
Volum
0,00
Alt 52 setmanes
1,48 €
Baix 52 setmanes
0,60 €
BPA
-0,17 €
Nombre d'empleats
152
NotĂcies
De fonts web i partners de notĂcies
qz.com
·
fa 41 minuts
NYSE CPO on American options extended trading hours
Simply Wall Street
·
fa 32 minuts
Why Is Recursion Pharmaceuticals (RXRX) Drawing Attention After AI Drug And Trial Milestones?
Kalkine Media
·
fa 10 minuts
Kimberly-Clark (NASDAQ:KMB) steps forward as the staples rotation builds
Yahoo Finance
·
fa 4 hores
Goldman Sachs is still betting on a nice year-end rally for the S&P 500
Perfil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Sobre Transgene SA